Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $131.75 million. The enterprise value is $6.68 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | Jan 16, 2026 |
Share Statistics
ORMP has 39.80 million shares outstanding. The number of shares has increased by 3.29% in one year.
| Current Share Class | 39.80M |
| Shares Outstanding | 39.80M |
| Shares Change (YoY) | +3.29% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 18.26% |
| Owned by Institutions (%) | 20.36% |
| Float | 29.37M |
Valuation Ratios
The trailing PE ratio is 2.21.
| PE Ratio | 2.21 |
| Forward PE | n/a |
| PS Ratio | 65.87 |
| Forward PS | n/a |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.10 |
| EV / Sales | 3.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.98, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.98 |
| Quick Ratio | 6.60 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 37.10% and return on invested capital (ROIC) is -16.35%.
| Return on Equity (ROE) | 37.10% |
| Return on Assets (ROA) | -4.88% |
| Return on Invested Capital (ROIC) | -16.35% |
| Return on Capital Employed (ROCE) | -7.12% |
| Weighted Average Cost of Capital (WACC) | 11.23% |
| Revenue Per Employee | $500,000 |
| Profits Per Employee | $16.01M |
| Employee Count | 4 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $11.31 million in taxes.
| Income Tax | 11.31M |
| Effective Tax Rate | 15.01% |
Stock Price Statistics
The stock price has increased by +40.25% in the last 52 weeks. The beta is 1.28, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | +40.25% |
| 50-Day Moving Average | 3.41 |
| 200-Day Moving Average | 2.68 |
| Relative Strength Index (RSI) | 45.33 |
| Average Volume (20 Days) | 130,683 |
Short Selling Information
The latest short interest is 541,599, so 1.36% of the outstanding shares have been sold short.
| Short Interest | 541,599 |
| Short Previous Month | 556,109 |
| Short % of Shares Out | 1.36% |
| Short % of Float | 1.84% |
| Short Ratio (days to cover) | 3.17 |
Income Statement
In the last 12 months, ORMP had revenue of $2.00 million and earned $64.05 million in profits. Earnings per share was $1.50.
| Revenue | 2.00M |
| Gross Profit | 13,000 |
| Operating Income | -15.09M |
| Pretax Income | 75.32M |
| Net Income | 64.05M |
| EBITDA | -14.97M |
| EBIT | -15.09M |
| Earnings Per Share (EPS) | $1.50 |
Full Income StatementBalance Sheet
The company has $125.89 million in cash and $825,000 in debt, with a net cash position of $125.07 million or $3.14 per share.
| Cash & Cash Equivalents | 125.89M |
| Total Debt | 825,000 |
| Net Cash | 125.07M |
| Net Cash Per Share | $3.14 |
| Equity (Book Value) | 199.74M |
| Book Value Per Share | 5.09 |
| Working Capital | 114.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.15 million and capital expenditures -$9,000, giving a free cash flow of -$10.61 million.
| Operating Cash Flow | -9.15M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 122,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.61M |
| FCF Per Share | -$0.27 |
Full Cash Flow StatementMargins
Gross margin is 0.65%, with operating and profit margins of -754.40% and 3,202.50%.
| Gross Margin | 0.65% |
| Operating Margin | -754.40% |
| Pretax Margin | 3,766.20% |
| Profit Margin | 3,202.50% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
